ICN37805 | CAS#1191237-80-5

MedKoo Cat#: 555831 | Name: ICN37805

Description:

WARNING: This product is for research use only, not for human or veterinary use.

ICN37805 is an important intermediate to synthesize antiviral drug remdesivir. This product has no formal name at the moment. For the convenience of communication, a temporary code name was therefore proposed according to MedKoo Chemical Nomenclature (see web page: https://www.medkoo.com/page/naming).

Chemical Structure

ICN37805

CAS#1191237-80-5 (free base)

Theoretical Analysis

MedKoo Cat#: 555831

Name: ICN37805

CAS#: 1191237-80-5 (free base)

Chemical Formula: C15H17N5O4

Exact Mass: 331.1281

Molecular Weight: 331.33

Elemental Analysis: C, 54.38; H, 5.17; N, 21.14; O, 19.31

Price and Availability

Size	Price	Availability
100mg	USD 150.00	2 Weeks
250mg	USD 250.00	2 Weeks
500mg	USD 400.00	2 Weeks
1g	USD 650.00	2 Weeks
2g	USD 950.00	2 Weeks
5g	USD 1,850.00	2 Weeks
10g	USD 2,950.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

1911579-00-4 (tosylate) 1191237-80-5 (free base)

Synonym

Remdesivir related compound 7; ICN37805; ICN-37805; ICN 37805; Remdesivir-intermediate.

IUPAC/Chemical Name

(3aR,4R,6R,6aR)-4-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-6-(hydroxymethyl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxole-4-carbonitrile

InChi Key

IJCOKJGMVJGKBB-CGEWXTDFSA-N

InChi Code

InChI=1S/C15H17N5O4/c1-14(2)23-11-9(5-21)22-15(6-16,12(11)24-14)10-4-3-8-13(17)18-7-19-20(8)10/h3-4,7,9,11-12,21H,5H2,1-2H3,(H2,17,18,19)/t9-,11-,12-,15+/m1/s1

SMILES Code

N#C[C@]1(O[C@@H]([C@H]2OC(C)(C)O[C@H]21)CO)C3=CC=C4C(N)=NC=NN43

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Product Data

Product Data

Instruction

View handling instruction

Biological target:

Remdesivir O-desphosphate acetonide impurity is an impurity of Remdesivir. Remdesivir (GS-5734), a nucleoside analogue with effective antiviral activity and is highly effective in the control of SARS-CoV-2 (COVID-19) infection in vitro.

In vitro activity:

In vitro, Remdesivir (RDV) exhibited antiviral activity against a clinical isolate of SARS-CoV-2 in primary human airway epithelial cells with a half-maximal effective concentration of 9.9 nM and also potently (280 nM) inhibited SARS-CoV-2 replication in Calu-3 human lung cells. In biochemical assays assessing RDV-triphosphate incorporation by the SARS-CoV-2, SARS-CoV, and MERS-CoV viral RNA-dependent RNA polymerase complexes, RDV triphosphate was selectively incorporated over the natural nucleotide substrate adenosine triphosphate and inhibited viral RNA synthesis with a half-maximal inhibitory concentration value of 32 nM for MERS-CoV. Reference: Clin Pharmacokinet. 2021 Mar 30 : 1–15. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8007387/

In vivo activity:

In vivo, Remdesivir (RDV) showed therapeutic efficacy in SARS-CoV-2-infected rhesus monkeys and prophylactic and therapeutic efficacy in MERS-CoV-infected rhesus monkeys. Briefly, 12 h after inoculation with SARS-CoV-2, rhesus monkeys received an RDV 10-mg/kg IV loading dose followed by maintenance doses of RDV 5 mg/kg at 24 h post-inoculation and once daily thereafter for a total of 6 days of treatment. The aim of the loading dose was to rapidly generate high GS-443902 concentrations following the first dose. Treatment with this regimen resulted in a significant reduction in clinical signs of respiratory disease, lung pathology and gross lung lesions, and viral RNA levels compared with vehicle-treated animals. Reference: Clin Pharmacokinet. 2021 Mar 30 : 1–15. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8007387/

	Solvent	mg/mL	mM
Solubility
	DMF	12.0	36.22
	DMSO	55.5	167.51
	Ethanol	5.0	15.09
	PBS (pH 7.2)	0.3	0.91

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 331.33 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

1. Humeniuk R, Mathias A, Kirby BJ, Lutz JD, Cao H, Osinusi A, Babusis D, Porter D, Wei X, Ling J, Reddy YS, German P. Pharmacokinetic, Pharmacodynamic, and Drug-Interaction Profile of Remdesivir, a SARS-CoV-2 Replication Inhibitor. Clin Pharmacokinet. 2021 Mar 30:1–15. doi: 10.1007/s40262-021-00984-5. Epub ahead of print. PMID: 33782830; PMCID: PMC8007387. 2. Buckland MS, Galloway JB, Fhogartaigh CN, Meredith L, Provine NM, Bloor S, Ogbe A, Zelek WM, Smielewska A, Yakovleva A, Mann T, Bergamaschi L, Turner L, Mescia F, Toonen EJM, Hackstein CP, Akther HD, Vieira VA, Ceron-Gutierrez L, Periselneris J, Kiani-Alikhan S, Grigoriadou S, Vaghela D, Lear SE, Török ME, Hamilton WL, Stockton J, Quick J, Nelson P, Hunter M, Coulter TI, Devlin L; CITIID-NIHR COVID-19 BioResource Collaboration; MRC-Toxicology Unit COVID-19 Consortium, Bradley JR, Smith KGC, Ouwehand WH, Estcourt L, Harvala H, Roberts DJ, Wilkinson IB, Screaton N, Loman N, Doffinger R, Lyons PA, Morgan BP, Goodfellow IG, Klenerman P, Lehner PJ, Matheson NJ, Thaventhiran JED. Treatment of COVID-19 with remdesivir in the absence of humoral immunity: a case report. Nat Commun. 2020 Dec 14;11(1):6385. doi: 10.1038/s41467-020-19761-2. PMID: 33318491; PMCID: PMC7736571.

In vitro protocol:

In vivo protocol:

1. Siegel D, Hui HC, Doerffler E, Clarke MO, Chun K, Zhang L, Neville S, Carra E, Lew W, Ross B, Wang Q, Wolfe L, Jordan R, Soloveva V, Knox J, Perry J, Perron M, Stray KM, Barauskas O, Feng JY, Xu Y, Lee G, Rheingold AL, Ray AS, Bannister R, Strickley R, Swaminathan S, Lee WA, Bavari S, Cihlar T, Lo MK, Warren TK, Mackman RL. Discovery and Synthesis of a Phosphoramidate Prodrug of a Pyrrolo[2,1-f][triazin-4-amino] Adenine C-Nucleoside (GS-5734) for the Treatment of Ebola and Emerging Viruses. J Med Chem. 2017 Mar 9;60(5):1648-1661. doi: 10.1021/acs.jmedchem.6b01594. Epub 2017 Feb 14. PMID: 28124907. 2. Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, Shi Z, Hu Z, Zhong W, Xiao G. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020 Mar;30(3):269-271. doi: 10.1038/s41422-020-0282-0. Epub 2020 Feb 4. PMID: 32020029; PMCID: PMC7054408.